Skip to main content
SpringerLink
Log in

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

New automated hematology analyzers have led to the availability of novel hematological parameters, including the immature platelet fraction (IPF) and the immature reticulocyte fraction (IRF), both of potential interest in patients with myeloproliferative neoplasms (MPNs). We performed a prospective analysis of 217 patients with MPN, including 32 (15%) with essential thrombocythemia (ET), 43 (20%) with polycythemia vera (PV), and 142 (65%) with myelofibrosis (MF); the IPF and IRF were measured by the Sysmex XN analyzer. As compared to patients with ET, both a higher IPF and IRF were observed among patients with PV and MF. Factors associated with high IPF among patients with PV/ET were male sex, thrombocytopenia, and diagnosis of PV; among patients with MF, they were elevated peripheral blasts, low platelet count, JAK2 V617F mutation, and previous therapy. Factors associated with high IRF among patients with PV/ET were low hemoglobin, high reticulocyte count, and PV diagnosis; among patients with MF, they were peripheral blasts and elevated reticulocytes. The IPF and IRF represent novel parameters in patients with MPN with potential relevant clinical implications. Comparison with healthy subjects and those with secondary polycythemia is needed to confirm our preliminary findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lecompte TP, Bernimoulin MP (2015) Novel parameters in blood cell counters. Clin Lab Med 35(1):209–224

    Article  PubMed  Google Scholar 

  2. Briggs C, Harrison P, Machin SJ (2007) Continuing developments with the automated platelet count. Int J Lab Hematol 29(2):77–91

    Article  CAS  PubMed  Google Scholar 

  3. Dusse LM, Freitas LG (2015) Clinical applicability of reticulated platelets. Clin Chim Acta 439:143–147

    Article  CAS  PubMed  Google Scholar 

  4. Hoffmann JJ (2014) Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 52(8):1107–1117

    Article  CAS  PubMed  Google Scholar 

  5. Thomas-Kaskel AK, Mattern D, Kohler G, Finke J, Behringer D (2007) Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation. Cytometry B Clin Cytom 72(4):241–248

    Article  PubMed  Google Scholar 

  6. Michur H, Maslanka K, Szczepinski A, Marianska B (2008) Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation. Int J Lab Hematol 30(6):519–525

    CAS  PubMed  Google Scholar 

  7. Briggs C, Hart D, Kunka S, Oguni S, Machin SJ (2006) Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med 16(2):101–109

    Article  CAS  PubMed  Google Scholar 

  8. Perl L, Lerman-Shivek H, Rechavia E et al (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63(6):513–517

    Article  CAS  PubMed  Google Scholar 

  9. Noronha JF, Costa FF, Saad ST, Lorand-Metze IG, Grotto HZ (2007) Evaluation of reticulated platelets in patients with sickle cell diseases. Thromb Res 121(2):259–267

    Article  CAS  PubMed  Google Scholar 

  10. Buttarello M (2016) Laboratory diagnosis of anemia: are the old and new red cell parameters useful in classification and treatment, how? Int J Lab Hematol 38(Suppl 1):123–132

    Article  PubMed  Google Scholar 

  11. Tsuda I, Tatsumi N (1989) Maturity of reticulocytes in various hematological disorders. Eur J Haematol 43(3):252–254

    Article  CAS  PubMed  Google Scholar 

  12. Davis BH, Bigelow NC (1994) Automated reticulocyte analysis. Clinical practice and associated new parameters. Hematol Oncol Clin North Am 8(4):617–630

    CAS  PubMed  Google Scholar 

  13. Chang CC, Kass L (1997) Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Am J Clin Pathol 108(1):69–73

    CAS  PubMed  Google Scholar 

  14. Torres Gomez A, Casano J, Sanchez J, Madrigal E, Blanco F, Alvarez MA (2003) Utility of reticulocyte maturation parameters in the differential diagnosis of macrocytic anemias. Clin Lab Haematol 25(5):283–288

    Article  CAS  PubMed  Google Scholar 

  15. Panova-Noeva M, Marchetti M, Buoro S et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118(9):2599–2601

    Article  CAS  PubMed  Google Scholar 

  16. Kissova J, Bulikova A, Ovesna P, Bourkova L, Penka M (2014) Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms. Int J Hematol 100(5):429–436

    Article  CAS  PubMed  Google Scholar 

  17. Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951

    Article  CAS  PubMed  Google Scholar 

  18. Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708

    Article  CAS  PubMed  Google Scholar 

  19. Nussenzveig RH, Swierczek SI, Jelinek J et al (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35(1):32–38

    Article  CAS  PubMed  Google Scholar 

  20. Ko YJ, Hur M, Kim H, Choi SG, Moon HW, Yun YM (2015) Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100. Clin Chem Lab Med 53(7):1091–1097

    Article  CAS  PubMed  Google Scholar 

  21. Tefferi A (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(9):915–925

    Article  CAS  PubMed  Google Scholar 

  22. Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(2):162–173

    Article  CAS  PubMed  Google Scholar 

  23. Hoffmann JJ, van den Broek NM, Curvers J (2013) Reference intervals of reticulated platelets and other platelet parameters and their associations. Arch Pathol Lab Med 137(11):1635–1640

    Article  PubMed  Google Scholar 

  24. Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392–397

    Article  PubMed  Google Scholar 

  25. Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477

    Article  CAS  PubMed  Google Scholar 

  26. Rumi E, Pietra D, Pascutto C et al (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062–1069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA

    Paolo Strati, Prithviraj Bose, Lindsey Lyle, Katie Gaw, Lingsha Zhou, Sherry A. Pierce, Julie Huynh-Lu, Cheryl F. Hirsch-Ginsberg, Daniel E. Bueso-Mendoza, Carlos E. Bueso-Ramos & Srdan Verstovsek

Authors
  1. Paolo Strati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prithviraj Bose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lindsey Lyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katie Gaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lingsha Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sherry A. Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julie Huynh-Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cheryl F. Hirsch-Ginsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel E. Bueso-Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Carlos E. Bueso-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Srdan Verstovsek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srdan Verstovsek.

Ethics declarations

This study was approved by the Institutional Review Board of MDACC and conducted in accordance with our institutional guidelines and the principles of the Declaration of Helsinki.

Authorship

SV designed the study, analyzed the data, provided clinical care to patients, and wrote the paper; PS designed the study, analyzed data, and wrote the paper; PB and JHL provided clinical care to patients and coauthored the paper; CBR, CFHG and DEBM measured and provided laboratory data and coauthored the paper; and KJ, LZ, and SP collected and analyzed the data and coauthored the paper.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strati, P., Bose, P., Lyle, L. et al. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol 96, 733–738 (2017). https://doi.org/10.1007/s00277-017-2956-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-2956-3

Keywords

Search

Navigation